JOHANNESBURG (Reuters) -South Africa’s Aspen Pharmacare reported a 5% rise in half-year earnings on Monday, buoyed by strong performances in both its commercial pharmaceuticals and manufacturing businesses.
For the six months to December 31, Africa’s biggest drugmaker recorded normalised headline earnings per share (HEPS) of 724.2 South African cents, up from 688.3 cents in the prior comparable year. On a constant currency basis, HEPS were up by 17%.
(Reporting by Nqobile Dludla, Editing by Louise Heavens)
Comments